Belgian Sperm Donor Scandal: Cancer-Causing Gene Affects Dozens of Children

A scandal involving a sperm donor with a cancer-causing gene mutation has come to light in Belgium, potentially impacting the health of 52 children conceived using his sperm. The situation raises serious ethical and regulatory questions about donor screening and the notification of affected families.

The Discovery and the Gene Mutation

In November 2023, the European Sperm Bank in Denmark issued a “rapid alert” regarding a donor carrying a mutation in the TP53 gene [1]. This mutation significantly increases the risk of developing various types of cancer and is hereditary. The TP53 gene mutation is associated with Li-Fraumeni syndrome, a rare condition that predisposes individuals to a wide range of cancers [3].

Timeline of Events and Affected Clinics

Between 2008 and 2017, 14 Belgian fertility clinics acquired sperm from the donor [1]. Of these, 12 clinics utilized the sperm in treatments for 37 women, resulting in the birth of 52 children [1], [2]. The donor is believed to have fathered at least 67 children globally [1].

Delayed Notification and Regulatory Concerns

The Federal Agency for Medicines and Health Products (FAMHP) was alerted to the potential risk in 2023, but Federal Health Minister Frank Vandenbroucke was not informed until earlier this week [1]. This delay has sparked criticism regarding the handling of the situation and the lack of a clear framework for adhering to Belgian legislation.

Current Status and Ongoing Investigations

Authorities are currently working to trace the affected families to inform them of the potential risk [1]. It remains unclear how many of the 52 children have inherited the TP53 gene mutation. Ten cases of cancer have already been diagnosed in Europe among children conceived with the donor’s sperm [2], but specific numbers for Belgian children are not yet available.

Broader Implications

This case highlights the need for improved oversight and regulation of sperm donor screening processes across Europe. The incident raises ethical questions about the balance between the right to have children and the right of a child to be born without a known hereditary risk of cancer.